IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

The hand sanitizer spray pen market is projected to grow at a CAGR of 11% over the forecast period, reaching a market value ...

Bone and Joint Health Supplement Market According to the Future Market Insights’ latest report, global sales of bone and ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief ...

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program 12.09.2024 / 12:57 CET/CEST The issuer is solely responsible for the content of this announcement.

Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, and appointments, here’s a quick look at which stocks will be in focus in today ...